Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH. Boss DS, et al. Among authors: ten bokkel huinink ww. Clin Cancer Res. 2009 Jul 1;15(13):4475-83. doi: 10.1158/1078-0432.CCR-08-3144. Epub 2009 Jun 16. Clin Cancer Res. 2009. PMID: 19531625 Clinical Trial.
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MG, ten Bokkel Huinink WW, van der Vijgh WJ, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH, Beijnen JH. Huizing MT, et al. Among authors: ten bokkel huinink ww. J Clin Oncol. 1997 Jan;15(1):317-29. doi: 10.1200/JCO.1997.15.1.317. J Clin Oncol. 1997. PMID: 8996159 Clinical Trial.
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW. Huizing MT, et al. Among authors: ten bokkel huinink ww. J Clin Oncol. 1997 May;15(5):1953-64. doi: 10.1200/JCO.1997.15.5.1953. J Clin Oncol. 1997. PMID: 9164207 Clinical Trial.
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW. Herben VM, et al. Among authors: ten bokkel huinink ww. J Clin Oncol. 1999 Mar;17(3):747-55. doi: 10.1200/JCO.1999.17.3.747. J Clin Oncol. 1999. PMID: 10071262 Clinical Trial.
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Panday VR, ten Bokkel Huinink WW, Vermorken JB, Rosing H, Koopman FJ, Swart M, Schellens JH, Beijnen JH. Panday VR, et al. Among authors: ten bokkel huinink ww. Pharmacol Res. 1999 Jul;40(1):67-74. doi: 10.1006/phrs.1999.0477. Pharmacol Res. 1999. PMID: 10378993 Clinical Trial.
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Nannan Panday VR, de Wit R, Schornagel JH, Schot M, Rosing H, Lieverst J, ten Bokkel Huinink WW, Schellens JH, Beijnen JH. Nannan Panday VR, et al. Among authors: ten bokkel huinink ww. Cancer Chemother Pharmacol. 1999;44(4):349-53. doi: 10.1007/s002800050988. Cancer Chemother Pharmacol. 1999. PMID: 10447584 Clinical Trial.
238 results